PLIANT THERAPEUTICS, INC. Increase (Decrease) in Accounts Receivable
PLIANT THERAPEUTICS, INC. (PLRX) reported Increase (Decrease) in Accounts Receivable of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2025-03-03
- PLIANT THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2024-12-31 was $0.00.
- PLIANT THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2024-09-30 was $0.00.
- PLIANT THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2024-06-30 was $0.00.
- PLIANT THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- PLIANT THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2024 was $0.00.
- PLIANT THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2023 was -$1.98M.
- PLIANT THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2022 was -$15.00K.
- PLIANT THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2021 was -$7.28M, a 426.94% decline from fiscal 2020.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $0.00 derived: sum of 2 quarters · filed 2025-03-03 | $0.00 derived: sum of 3 quarters · filed 2025-03-03 | $0.00 10-K · filed 2025-03-03 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 4 quarters · filed 2025-03-03 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 | $0.00 derived: sum of 3 quarters · filed 2025-03-03 | -$1.58M derived: sum of 4 quarters · filed 2025-03-03 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-06 | $0.00 derived: sum of 2 quarters · filed 2025-03-03 | -$1.58M derived: sum of 3 quarters · filed 2025-03-03 | -$3.30M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$1.58M derived: sum of 2 quarters · filed 2025-03-03 | -$3.30M derived: sum of 3 quarters · filed 2025-03-03 | -$1.98M 10-K · filed 2025-03-03 |
| 2023-09-30 | -$1.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$3.30M derived: sum of 2 quarters · filed 2024-11-07 | -$1.98M 10-Q · filed 2024-11-07 | -$1.48M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | -$1.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$403.00K 10-Q · filed 2024-08-07 | $98.00K derived: sum of 3 quarters · filed 2025-03-03 | -$3.41M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $1.31M 10-Q · filed 2024-05-06 | $1.81M derived: sum of 2 quarters · filed 2025-03-03 | -$1.69M derived: sum of 3 quarters · filed 2025-03-03 | $2.05M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $501.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$3.01M derived: sum of 2 quarters · filed 2025-03-03 | $734.00K derived: sum of 3 quarters · filed 2025-03-03 | -$15.00K 10-K · filed 2025-03-03 |
| 2022-09-30 | -$3.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $233.00K derived: sum of 2 quarters · filed 2023-11-09 | -$516.00K 10-Q · filed 2023-11-09 | -$128.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $3.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $2.99M 10-Q · filed 2023-08-09 | $3.38M derived: sum of 3 quarters · filed 2024-02-27 | $3.16M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$749.00K 10-Q · filed 2023-05-09 | -$361.00K derived: sum of 2 quarters · filed 2024-02-27 | -$581.00K derived: sum of 3 quarters · filed 2024-02-27 | -$925.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $388.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $168.00K derived: sum of 2 quarters · filed 2024-02-27 | -$176.00K derived: sum of 3 quarters · filed 2024-02-27 | -$7.28M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$220.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$564.00K derived: sum of 2 quarters · filed 2022-11-08 | -$7.67M 10-Q · filed 2022-11-08 | -$5.52M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$344.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$7.45M 10-Q · filed 2022-08-08 | -$5.30M derived: sum of 3 quarters · filed 2022-08-08 | -$1.77M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$7.11M 10-Q · filed 2022-05-09 | -$4.96M derived: sum of 2 quarters · filed 2022-05-09 | -$1.43M derived: sum of 3 quarters · filed 2022-05-09 | -$29.59M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $2.15M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $5.68M derived: sum of 2 quarters · filed 2022-03-01 | -$22.48M derived: sum of 3 quarters · filed 2022-03-01 | $2.23M 10-K · filed 2022-03-01 |
| 2020-09-30 | $3.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$24.63M derived: sum of 2 quarters · filed 2021-11-09 | $79.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | -$28.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$3.45M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $24.71M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $7.05M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |